No Discrepancy between in Vivo Gene Marking Efficiency Assessed in Peripheral Blood Populations Compared with Bone Marrow Progenitors or CD34+ Cells
- 1 March 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (4) , 633-640
- https://doi.org/10.1089/10430349950018706
Abstract
Reports of 1- to 2-log higher gene transfer levels in purified CD34+ cells or marrow CFU compared with levels in mature circulating blood cells after transplantation of retrovirally transduced primitive human hematopoietic cells have resulted in concern that transduced progenitors do not contribute proportionally to ongoing hematopoiesis (Kohn et al., 1995; Brenner, 1996). To study the issue in a relevant large animal, we analyzed samples of mature blood cells, marrow CD34-enriched cells and marrow CD34-depleted cells, and marrow CFU from a cohort of 11 rhesus transplanted with retrovirally transduced cells and followed for up to 5.5 years. They were transplanted with CD34-enriched bone marrow (BM) or G-CSF/SCF-mobilized peripheral blood (PB) cells transduced with vectors containing either neo , human glucocerebrosidase, or murine adenosine deaminase genes. There were no significant differences between the levels of vector sequences found in BM CD34+ cells, BM CD34- cells, PB granulocytes, or PB mononuclear cells (MNCs) in any animal. In four animals transplanted with SCF/G-CSF-primed BM cells and analyzed 3-6 months posttransplantation, the percentage of CFU containing the neo vector appeared to be 1 log higher than the representation of marked cells in the PB of these animals, but this discrepancy did not persist at time points greater than 6 months posttransplantation. The level of CFU marking was no higher than PB granulocyte or MNC marking at any time points in the other animals. Low levels of mature gene-modified cells probably reflect poor transduction of repopulating stem cells, not a block in differentiation or specific immune rejection of mature cells. This study represents the longest follow-up of primates transplanted with transduced hematopoietic cells, and it is encouraging that the levels of vector-containing cells appear stable for up to 5 years.Keywords
This publication has 32 references indexed in Scilit:
- Murine Bone Marrow Expressing the Neomycin Resistance Gene Has No Competitive Disadvantage AssessedIn VivoHuman Gene Therapy, 1998
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997
- Gene MarkingHuman Gene Therapy, 1996
- Retroviral Gene Transfer in Autologous Bone Marrow Transplantation for Adult Acute LeukemiaHuman Gene Therapy, 1996
- Gene marking and gene therapy directed at primary hematopoietic cellsCurrent Opinion in Hematology, 1996
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993
- Retroviral vectors for persistent expression in vivoCurrent Opinion in Biotechnology, 1992
- Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.The Journal of Experimental Medicine, 1992
- Antigen CD34+ marrow cells engraft lethally irradiated baboons.Journal of Clinical Investigation, 1988
- Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model.Journal of Clinical Investigation, 1987